- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Kamada(KMDA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for KMDA
11/13/2026: KMDA (1-star) is currently NOT-A-BUY. Pass it for now.
Kamada Ltd. is a global biopharmaceutical company specializing in plasma-derived protein therapeutics and commercial distribution. The company benefits from solid execution, high U.S. market share for its flagship rabies product KEDRAB, and double-digit revenue and earnings growth. Its primary investment story centers on expanding high-margin proprietary drug sales and strong cash generation. However, investors must monitor single-product revenue concentration, intense competition from global giants, and manufacturing execution risks. The stock suits growth and value investors seeking exposure to specialty pharmaceuticals, supported by regular dividend distributions and positive operational momentum.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit while signal remains positive | Kamada delivers consistent double-digit revenue and earnings expansion driven by core portfolio demand. |
| Momentum investor | Strong fit while signal remains positive | Positive earnings beats, raised annual guidance, and upward stock momentum make it attractive conditional on technical strength. |
| Value investor | Strong fit | The stock trades at a reasonable P/E multiple backed by solid profitability, positive cash flow, and tangible net income. |
| Dividend investor | Mixed fit | While the company pays periodic cash dividends, it is primarily a growth-oriented small-cap biopharma rather than a dedicated high-yield income stock. |
| Low-risk investor | Weak fit | As a small-cap biotechnology company subject to regulatory, clinical, and market execution risks, it involves moderate volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | Small-cap biotechnology stocks frequently experience swings based on earnings announcements and sector sentiment. |
| Valuation risk | Medium | |
| Competition risk from large plasma conglomerates | Medium / high | Global giants possess larger balance sheets and economies of scale in plasma collection. |
| Business quality | Medium / high | Kamada features specialized proprietary assets and robust margins, though tempered by product concentration. |
| Dividend income | Low | Dividend payouts are opportunistic and variable rather than core fixed-income distributions. |
| Execution risk | Medium | Success relies heavily on maintaining manufacturing compliance, scaling distribution, and executing business development. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 467.05M USD | Price to earnings Ratio 21.29 | 1Y Target Price 13.75 |
Price to earnings Ratio 21.29 | 1Y Target Price 13.75 | ||
Volume (30-day avg) 103.8K shares | Beta 0.2 | 52 Weeks Range 6.28 - 8.96 | Updated Date 11/15/2026 |
52 Weeks Range 6.28 - 8.96 | Updated Date 11/15/2026 | ||
Dividends yield (FY) 2.11% | Basic EPS (TTM) 0.38 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Drug Manufacturers - Specialty & Generic
- BUY participation
- 66.7%
- Active BUY / eligible
- 8 / 12
- 30-Day BUY Count Change
- +3
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Downtrend
The stock has experienced a sustained decline in price over recent periods.

Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 26.94% | Avg. Invested days 53 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Proprietary Products | Sales of specialized plasma-derived therapeutics like KEDRAB, GLASSIA, VARIZIG, and HEPAGAM B manufactured via proprietary processes. | This is the primary high-margin earnings engine of the company. |
| Distribution Segment | Commercialization and marketing of third-party pharmaceutical and vaccine products within the Israeli market. | Provides a steady, reliable secondary stream of localized cash flow. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-09 | When Before Market | Estimate 0.13 | Actual 0.14 |
Profitability
Profit Margin 12.67% | Operating Margin (TTM) 15.43% |
Management Effectiveness
Return on Assets (TTM) 5% | Return on Equity (TTM) 9.35% |
Valuation
Trailing PE 21.29 | Forward PE 16.08 | Enterprise Value 413.24M | Price to Sales(TTM) 2.37 |
Enterprise Value 413.24M | Price to Sales(TTM) 2.37 | ||
Enterprise Value to Revenue 2.1 | Enterprise Value to EBITDA 8.88 | Shares Outstanding 57.73M | Shares Floating 32.72M |
Shares Outstanding 57.73M | Shares Floating 32.72M | ||
Percent Insiders 7.11 | Percent Institutions 49.35 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

